Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Antibody | 2 |
Synthetic peptide | 2 |
Radionuclide Drug Conjugates (RDC) | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism NSD2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HNRNPA2B1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 Aug 2024 |
Sponsor / Collaborator |
Start Date04 Mar 2019 |
Sponsor / Collaborator |
Start Date25 Apr 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
64Cu-PCB-TE2A-Tz ( HNRNPA2B1 ) | Triple Negative Breast Cancer More | Preclinical |
BJ-1108 | Colitis More | Preclinical |
LEM-06 ( NSD2 ) | Multiple Myeloma More | Preclinical |
KARI-201 ( GHSR x SMPD1 ) | Alzheimer Disease More | Preclinical |
MFK-902 ( MMP2 ) | Arthritis More | Preclinical |